Arab Israeli Conflict
Middle East News
Hi Tech News
Mylan rejected Teva's $41 billion bid earlier this week.
Acquisition would create leading company with potential to transform global market for generics.
Teva sought stay of lower court ruling that favored developers of generic versions of its top selling multiple sclerosis drug.
Stock price lowest since 2000
By MAX SCHINDLER
About 40 million Americans suffer from migraines - intense headaches characterized by throbbing pain and sensitivity to light and nausea.
Mylan NV received the green light to produce a copycat version of Teva’s blockbuster drug, Copaxone, which is already on its way to American patients.
Social Finance Israel, led by Yaron Neudorfer and his team, has dipped its toe into the water.
By SHLOMO MAITAL
Kare Shultz, currently at Danish Lundbeck, will be tasked with steering the Israeli-based company out of its recent hardships.
Once dominant Israeli drug company Teva Pharmaceuticals continues to be battered.
The Israeli pharmaceutical company opened 17.5% lower in Tel Aviv this morning after losing 17.8% on Thursday.
By NIV ELIS
Teva CEO says acquisition delivers on strategy of increasing presence in key emerging markets.
Deal will further enhance Teva’s goals of delivering the highest quality medicines at the most competitive prices, Israeli company says.
By NIV ELIS,REUTERS
Please insert a valid email address